TetraLogic Pharmaceuticals Corporation (TetraLogic) is a clinical-stage biopharmaceutical company. The Company focuses on discovering and developing novel small molecule therapeutics that mimic Second Mitochondrial Activator of Caspases (SMAC)-mimetics, and are designed to cause or enable abnormal cells that are resistant to the body's immune system to self-destruct. Birinapant, its clinical-stage product candidate, is being tested in Phase I and Phase II oncology clinical trials for multiple solid tumors and hematological malignancies. The Company’s clinical trials of birinapant have enrolled over 275 subjects. The Company’s lead program is colorectal cancer (CRC), where it has substantially completed a Phase I/II clinical trial. TetraLogic's lead Smac mimetic drug, birinapant (formerly TL32711), is in Phase II clinical trials and is being developed for both solid tumors and hematological malignancies as a single agent and in combination with several standard-of-care cancer therapies.
Address
343 PHOENIXVILLE PIKE
MALVERN, PA 19355
United States
MALVERN, PA 19355
United States
